() infection is widely prevalent worldwide. infection has been reported to be a risk factor for the development of insulin resistance, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), liver fibrosis, and cirrhosis. Because treatment for NAFLD, other than weight loss is limited, the treatment for infection is well established. It is important to determine whether screening and treatment for H. pylori infection should be considered in patients with no gastrointestinal symptoms. The aim of this mini-review is to evaluate the association between infection and NAFLD including epidemiology, pathogenesis, and the evidence for infection as a modifiable risk factor for preventing or treating NAFLD.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037521 | PMC |
http://dx.doi.org/10.14218/JCTH.2022.00362 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!